Prevalence of hepatic steatosis and fibrosis in Turner syndrome: A prospective case–control study

Patrick Twohig,Ling Li,David Danford,Mary Craft,Anji T. Yetman
DOI: https://doi.org/10.1111/liv.15840
IF: 8.754
2024-02-25
Liver International
Abstract:Background and Aims Abnormal liver chemistries are common in Turner syndrome (TS). Guidelines suggest that TS patients undergo annual screening of liver enzymes, but the role of non‐invasive screening for steatosis and fibrosis is not clearly defined. We compared the prevalence of hepatic steatosis and fibrosis among TS patients to healthy controls using ultrasound with shear‐wave elastography (SWE) and assessed for risk factors associated with steatosis and fibrosis in TS. Methods Prospective case–control study of TS versus control patients from 2019 to 2021. All patients underwent abdominal ultrasound with doppler and SWE to assess hepatic fibrosis and steatosis. Risk factors were compared between TS and controls, as well as within the TS group. Results A total of 55 TS and 50 control patients were included. Mean age was 23.6 years vs. 24.6 years in the control group (p = .75). TS patients had significantly more steatosis (65% vs. 12%, stage 1 vs. 0, p
gastroenterology & hepatology
What problem does this paper attempt to address?